Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
Rhea-AI Summary
Ocugen (NASDAQ: OCGN) announced that Dr. Shankar Musunuri, chairman and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 from 9:45–10:25 a.m. PST in the Colonial Room, Mezzanine. Company executives will hold one-on-one meetings in San Francisco the week of January 12–15 to discuss strategy and partnership opportunities.
Ocugen said it is on a path toward filing three BLAs in the next two years, including a rolling BLA for OCU400 for retinitis pigmentosa in 2026. A live webcast will be available on the company events page and a limited-time replay will follow the presentation.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, OCGN gained 0.67%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Several biotech peers show declines (e.g., FDMT -5.19%, DSGN -6.71%, MBX -4.63%), but the momentum scanner did not flag a coordinated sector move, suggesting OCGN’s -6.29% drop may be more stock-specific.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Conference presentation | Positive | +1.6% | CEO presentation at Oppenheimer rare disease summit and investor meetings. |
| Nov 20 | Conference presentation | Positive | -2.6% | NobleCon21 presentation and strategy discussion on three BLAs in three years. |
| Nov 05 | Earnings and update | Positive | -1.4% | Q3 2025 financial results plus clinical and partnership progress update. |
| Oct 23 | Earnings call notice | Neutral | +1.3% | Scheduling webcast to discuss Q3 2025 earnings and business updates. |
| Oct 02 | Multiple conferences | Positive | +5.4% | Participation in three October conferences and reiteration of BLA goals. |
Conference-related announcements have often been positive in tone, with mixed price reactions—some modest gains and one notably strong move, alongside a couple of divergences on business/earnings updates.
Over the past few months, Ocugen has frequently highlighted its modifier gene therapy platform and plans for multiple BLAs, mainly through conference appearances and business updates. Notable events include October 2025 conference participation and a Q3 2025 business/financial update. Price reactions have alternated between positive and negative around these disclosures, showing no consistent pattern. Today’s J.P. Morgan conference presentation fits this ongoing investor-outreach and catalyst-framing narrative for 2026.
Market Pulse Summary
This announcement highlights Ocugen’s visibility at a major healthcare investor conference and reiterates plans for a catalyst-rich 2026, including three planned BLAs and a rolling BLA for OCU400 in retinitis pigmentosa. It extends a pattern of active conference participation and investor outreach. Observers may track actual BLA filings, clinical readouts, and any additional financing or regulatory disclosures as key markers of execution against these stated goals.
Key Terms
modifier gene therapy platform medical
retinitis pigmentosa medical
AI-generated analysis. Not financial advice.
MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, will present at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026, at The Westin St. Francis in San Francisco, CA.
“Year over year, Ocugen’s presence at the JPM Healthcare Conference has evolved and we are delighted to share the potential of our modifier gene therapy platform along with clinical development progress,” said Dr. Musunuri. “This premier conference is the optimal way to kick off Ocugen’s catalyst-rich 2026 and engage in critical conversations with potential strategic partners and the investment community.”
In addition to Dr. Musunuri’s session, members of Ocugen’s executive team will be on site in San Franciso all week to conduct one-on-one meetings highlighting the Company’s business strategy on the path toward filing three BLAs in the next two years including the rolling BLA of OCU400 for retinitis pigmentosa this year.
Details regarding the presentation are as follows:
Date: Thursday, January 15, 2026
Time: 9:45 - 10:25 a.m. PST
Location: Colonial Room, Mezzanine
A live video webcast of the presentation will be available on the events page of the Ocugen investor site. The webcast replay will be available for a limited time following the event.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com
FAQ
When and where will Ocugen (OCGN) present at the J.P. Morgan 2026 Healthcare Conference?
Will Ocugen (OCGN) provide a webcast of the J.P. Morgan presentation?
What program updates will Ocugen (OCGN) highlight at J.P. Morgan 2026?
How many BLAs does Ocugen (OCGN) plan to file and on what timeline?
Can investors meet Ocugen (OCGN) executives at J.P. Morgan 2026?
What is OCU400 and why is it notable for Ocugen (OCGN) in 2026?
